ZAG-a novel biomarker for cardiovascular risk in ESRD patients?

ZAG-a novel biomarker for cardiovascular risk in ESRD patients?
复制标题

ZAG——ESRD 患者心血管风险的新型生物标志物?

DOI:
10.1016/j.kint.2018.08.010
复制
发表时间:
2018
影响因子:
19.6
通讯作者:
Schmitt R
Schmitt R
中科院分区:
医学1区
文献类型:
--
作者:
Schmitt R

文献摘要

参考文献

相似文献

终末期肾病(ESRD)与极高的心血管疾病风险相关。传统的危险因素在ESRD中起着不同的作用,这促使人们寻找新的机制和生物标志物。在一项观察性研究中,Boucharaet等人发现锌- α - 2糖蛋白(ZAG)是透析患者心血管事件和死亡率的预后标志物。尽管这项研究提出了一些重要的问题,但研究结果应该谨慎解读,并需要在独立研究中得到证实。
End-stage renal disease (ESRD) is associated with an exceedingly high risk of cardiovascular disease. Traditional risk factors function differently in ESRD, which has prompted a search for novel mechanisms and biomarkers. In an observational study, Boucharaet al.identified zinc-alpha2-glycoprotein (ZAG) as a prognostic marker for cardiovascular events and mortality in patients on dialysis. Although the study raises important questions, the results should be interpreted cautiously and need to be confirmed in independent studies.
DOI: 10.1681/asn.2014050485
发表时间: 2015-11-01
影响因子: 13.6
作者:
Soerensen-Zender, Inga;Bhayana, Sagar;Schmitt, Roland
通讯作者: Schmitt, Roland
DOI: 10.1681/asn.2008010035
发表时间: 2008-12-01
影响因子: 13.6
作者:
Schmitt, Roland;Marlier, Arnaud;Cantley, Lloyd G.
通讯作者: Cantley, Lloyd G.
DOI: 10.1016/j.metabol.2010.06.019
发表时间: 2011-05-01
影响因子: 9.8
作者:
Philipp, Anne;Kralisch, Susan;Fasshauer, Mathias
通讯作者: Fasshauer, Mathias